Objective: To study the antiviral effects of components from Reduning injection against coxsachievirus A16 (CoxA16) and enterovirus 71 (EV71) in vitro. Method: African green monkey cell(Vero cells)

infected with 50 times 50% tissue cuture infective dose(TCID50) CoxA16 and EV71

were treated with components (15.625-500 mg · L-1) for 3 days (n=3)

median toxic concentration(TC50) values were clarified. The antiviral activity of components against CoxA16 and EV71 was assessed. Viral load was detected after active components application with optium concentration for 8 h. Result: Firstly

the toxic effects (TC50) of the components (RDN1-19) on Vero cells were investigated

which was from more than 1 000 to 221 mg · L-1. Furthermore

the antivirus and dose-response relationship studies of components showed that RDN7 and RDN18 revealed antiviral activity against CoxA16 with concentration for 50% of maximum effect(EC50) 460

92 mg · L-1

therapeutic index(TI) 1.44

2.40.Meanwhile

RDN6 and RDN17 revealed antiviral activity against EV71 with EC50 395

378 mg · L-1

TI 2.22

1.10.Finally

investigation on viral load indicated that RDN7 reduced CoxA16 copies very significantly in Vero cell (P<0.01). And RDN6

RDN 17 depressed EV71 copies very obviously in Vero cells (P<0.01). However

RDN18 failed to change CoxA16 and EV71 load clearly. Conclusion: The exogenous antiviral activity of components from Reduning injection against CoxA16 and EV71 could be clarified.